Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Development programs currently in clinical studies by Year
Development programs currently in clinical studies (programs)
Moderna Development programs currently in clinical studies: 35.00 programs in FY2025, down 14.6% from a year earlier.
Latest, FY2025
35.00
Period ended Dec 31, 2025
Change on a year earlier
-14.6%
41.00 in FY2024
History
7 years
Since FY2018
Sources
7
Documents cited below
Where the FY2025 figure comes from
“Additionally, we also have a diverse development pipeline of 25 development candidates across our 35 development programs currently in clinical studies.”
Source: FY2025 10-K ↗
Reported in Form 10-Q / 10-K Note 1, MD&A & Form 8-K Earnings Releases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Development programs currently in clinical studies (programs) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35.00 | -14.6% | FY2025 10-K ↗ |
| FY2024 | Dec 31, 2024 | 41.00 | +2.5% | FY2024 10-K ↗ |
| FY2023 | Dec 31, 2023 | 40.00 | +5.3% | FY2023 10-K ↗ |
| FY2022 | Dec 31, 2022 | 38.00 | +52.0% | Q4 2022 Earnings Release (8-K) ↗ |
| FY2021 | Dec 31, 2021 | 25.00 | – | Q4 2021 Earnings Release (8-K) ↗ |
| FY2019 | Dec 31, 2019 | 12.00 | +9.1% | FY2019 10-K ↗ |
| FY2018 | Dec 31, 2018 | 11.00 | – | FY2018 10-K ↗ |
Cite this data
StockData. (2026). Moderna Development programs currently in clinical studies, annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/pipeline-clinical
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.